JPH0337710B2 - - Google Patents
Info
- Publication number
- JPH0337710B2 JPH0337710B2 JP20337482A JP20337482A JPH0337710B2 JP H0337710 B2 JPH0337710 B2 JP H0337710B2 JP 20337482 A JP20337482 A JP 20337482A JP 20337482 A JP20337482 A JP 20337482A JP H0337710 B2 JPH0337710 B2 JP H0337710B2
- Authority
- JP
- Japan
- Prior art keywords
- liver
- peaks
- serum
- liquid chromatography
- analysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 19
- 208000019423 liver disease Diseases 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- 238000004811 liquid chromatography Methods 0.000 claims description 9
- 150000007519 polyprotic acids Polymers 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 12
- 208000019425 cirrhosis of liver Diseases 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 238000012742 biochemical analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 2
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- -1 silane compound Chemical class 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20337482A JPS5992348A (ja) | 1982-11-19 | 1982-11-19 | 生体試料の分析方法 |
| EP83304555A EP0102769B1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| DE8383304555T DE3374604D1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| CA000433955A CA1220700A (en) | 1982-08-06 | 1983-08-05 | Aqueous solution as an eluant used in liquid chromatography |
| US06/795,275 US4666861A (en) | 1982-08-06 | 1985-11-05 | Aqueous solution as an eluent used in liquid chromatography |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20337482A JPS5992348A (ja) | 1982-11-19 | 1982-11-19 | 生体試料の分析方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5992348A JPS5992348A (ja) | 1984-05-28 |
| JPH0337710B2 true JPH0337710B2 (enrdf_load_stackoverflow) | 1991-06-06 |
Family
ID=16472969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20337482A Granted JPS5992348A (ja) | 1982-08-06 | 1982-11-19 | 生体試料の分析方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5992348A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63205565A (ja) * | 1987-02-20 | 1988-08-25 | Toshihito Hiraoka | 肝機能検査方法 |
| CN104101679A (zh) * | 2014-07-24 | 2014-10-15 | 天津市第一中心医院 | 反相-高效液相色谱对人体血液和尿液中草酸浓度的测定方法 |
-
1982
- 1982-11-19 JP JP20337482A patent/JPS5992348A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5992348A (ja) | 1984-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dams et al. | LC− atmospheric pressure chemical ionization-MS/MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation | |
| JP7109597B2 (ja) | Ｌｃ－ｍｓ／ｍｓのための簡易化した生体試料の処理 | |
| Marsilio et al. | Simultaneous HPLC determination with light-scattering detection of lactulose and mannitol in studies of intestinal permeability in pediatrics | |
| JP5325973B2 (ja) | 分析装置 | |
| Iadarola et al. | Recent applications of CE‐and HPLC‐MS in the analysis of human fluids | |
| CN112630311A (zh) | 用于检测情感障碍的代谢标记物和试剂盒及使用方法 | |
| EP2628002B1 (en) | Analyte detection method | |
| CN117420245A (zh) | 一种人干血斑神经酰胺的检测方法及用于检测神经酰胺的试剂盒 | |
| Preeti et al. | Estimation of serum creatinine by routine Jaffé’s method and by dry chemistry in icteric and hemolytic serum samples | |
| CN112611814B (zh) | 一种干血片中1,5-脱水葡萄糖醇的测定方法 | |
| JPH0337710B2 (enrdf_load_stackoverflow) | ||
| Castro-Castro et al. | The first case of chronic otitis media due to Kerstersia gyiorum in Korea | |
| JPH0337711B2 (enrdf_load_stackoverflow) | ||
| JP4144117B2 (ja) | グルコースの測定方法及び測定装置 | |
| HIRAOKA et al. | Capillary-zone electrophoretic analyses of the proteins and amino acid components in cerebrospinal fluid of central nervous system diseases | |
| Becerra et al. | Miniaturized imprinted solid phase extraction to the selective analysis of Coenzyme Q10 in urine | |
| Jeong et al. | A pulsed amperometric detection method of galactose 1-phosphate for galactosemia diagnosis | |
| JP2518256B2 (ja) | バニリルマンデル酸、ホモバニリン酸およびクレアチニンの同時分析方法およびその装置 | |
| CN112903846A (zh) | 一种测定利伐沙班及其杂质的分析方法 | |
| JPH0337709B2 (enrdf_load_stackoverflow) | ||
| RU2220755C1 (ru) | Способ разделения смеси жирных кислот фракции c2-c6 методом газожидкостной хроматографии | |
| Lauri et al. | Optical dialysis adequacy monitoring: small uremic toxins and contribution to UV-absorbance studied by HPLC | |
| EP0102769B1 (en) | Eluent for liquid chromatography | |
| JP3664278B2 (ja) | 血漿または血清試料の調製方法 | |
| GB2042557A (en) | Filler composition for use in liquid chromatography |